![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 38/48 | (2006.01) |
A61K 38/4846 | (2013.01) | ||
C12N 9/64 | (2006.01) | ||
C12Y 304/21022 | (2013.01) | ||
C12N 9/644 | (2013.01) | ||
A61K 9/0019 | (2013.01) | ||
A61K 47/643 | (2017.08) |
(11) | Number of the document | 3645034 |
(13) | Kind of document | T |
(96) | European patent application number | 18736860.0 |
Date of filing the European patent application | 2018-06-29 | |
(97) | Date of publication of the European application | 2020-05-06 |
(45) | Date of publication and mention of the grant of the patent | 2023-08-30 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/EP2018/067523 |
Date | 2018-06-29 |
(87) | Number | WO 2019/002532 |
Date | 2019-01-03 |
(30) | Number | Date | Country code |
201762526377 P | 2017-06-29 | US |
(72) |
LI, Yanyan , US
BENSEN-KENNEDY, Debra , US
JACOBS, Iris , US
VOIGT, Christine , US
|
(73) |
CSL Behring Lengnau AG ,
Biotech Innovation Park, 2543 Lengnau BE,
CH
|
(54) | 21-DAY DOSING REGIMEN FOR FUSION PROTEINS COMPRISING FACTOR IX AND HUMAN ALBUMIN FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF |
21-DAY DOSING REGIMEN FOR FUSION PROTEINS COMPRISING FACTOR IX AND HUMAN ALBUMIN FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF |